TITLE

JUPITER lights up New Orleans sky

PUB. DATE
January 2009
SOURCE
CMAJ: Canadian Medical Association Journal;1/6/2009 Conference Reports, Vol. 180, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on developments and updates on tools and methods in assessing and managing cardiovascular risk. The American Heart Association released the therapeutic use of statin and the use of high-sensitivity C-reactive protein. It is mentioned that the use of statin can reduce the prevalence of cardiovascular events in patients with normal cholesterol levels but have an elevated high-sensitivity C-reactive protein. Updates on the result of Justification for the Use of Statins in Prevention: an Intervention Trial Evaluation Rosuvastin (JUPITER) are presented.
ACCESSION #
36348297

 

Related Articles

  • Assessing cardiac risk factors: is a rethink in order?  // CMAJ: Canadian Medical Association Journal;1/6/2009 Conference Reports, Vol. 180, p1 

    The article offers information on developments and updates on tools and methods in assessing and managing cardiovascular risk. The American Heart Association released the risk markers and appropriate use of statins. It is argued that the use of statin can reduce the prevalence of cardiovascular...

  • Experts Debate Meaning of JUPITER for Clinical Practice. Kuznar, Wayne // American Health & Drug Benefits;Nov/Dec2008, Vol. 1 Issue 9, p47 

    The article addresses the debate over the findings from the study "Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin" (JUPITER) published in the "New England Journal of Medicine." The study revealed that healthy people with unremarkable...

  • C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. Bikdeli, Behnood // Cardiovascular Drugs & Therapy;Dec2011, Vol. 25 Issue 6, p545 

    The association between C-reactive protein (CRP) and cardiovascular disease has been under investigation for more than sixty years. Lately, findings from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial opened a new frontier:...

  • Early, Intensive and Long-term Statin Therapy in Acute Coronary Syndrome: Focus on Anti-inflammatory Mechanisms. Jian-Jun Li; Sheng-Shou Hu // Vascular Disease Prevention;Jul2005, Vol. 2 Issue 3, p181 

    An acceptable concept is that the acute coronary syndrome (ACS) is related to erosion or rupture of vulnerable plaques leading to intracoronary thrombosis as a result of the activation of the coagulation cascade and platelet aggregation. Clinical trials and animal models suggest an inflammatory...

  • STATlN THERAPY, C-REACTIVE PROTEIN LEVELS, AND RISK OF FUTURE ADVERSE CORONARY EVENTS: A PROSPECTIVE OBSERVATIONAL STUDY. Russell, C. J. H.; Exley, A. R.; Buckenham, S. J.; Jarrett, E. J.; Marshall, C. J.; Charman, S. C.; Bennett, M. R.; Shapiro, L.; Ritchie, A. J. // Heart;May2004 Supplement 3, Vol. 90, pA13 

    This article presents a study on station therapy, AC-reactive protein levels, and risk of future adverse coronary events. Clinical trials of statin therapy report reductions in morbidity and mortality exceeding that predicted by the actual reduction in serum lipid achieved. These findings...

  • NICE triggers row over rationing of statins... Wilkinson, Emma // Pulse;6/25/2005, Vol. 65 Issue 25, p1 

    Reports on the issuance of a draft appraisal by the National Institute for Clinical Excellence authorizing a limited expansion on the use of statins in Great Britain. Release of a guidance by the Joint British Society recommending statins for cardiovascular disease risk; Availability of statins...

  • Registrar: MRCCP Exam update - C-reactive protein and CHD. Newson, Louise // GP: General Practitioner;12/2/2005, p80 

    The article reports that C-reactive protein (CRP) is a sensitive marker of inflammation. Elevated CRP levels are usually accompanied by high cholesterol levels and high levels of other traditional cardiovascular disease risk factors. One study showed that middle-aged men without cardiovascular...

  • High-sensitive factor I and C-reactive protein based biomarkers for coronary artery disease. Qing Zhao; Jian-Shi Du; Dong-Mei Han; Ying Ma // International Journal of Clinical & Experimental Medicine;2014, Vol. 7 Issue 12, p5158 

    An analysis of high-sensitive factor I and C-reactive proteins as biomarkers for coronary artery disease has been performed from 19 anticipated cohort studies that included 21,567 participants having no information about coronary artery disease. Besides, the clinical implications of statin...

  • High dose statins lower C reactive protein. Ridker, P. M.; Cannon, C. P.; Morrow, D. // BMJ: British Medical Journal (International Edition);4/23/2005, Vol. 330 Issue 7497, preceding p915 

    Answers a question of whether C reactive protein (CRP) is associated with a risk of recurrent coronary events. Research comparing atorvastatin and pravastatin; Finding of a linear relationship between reduction in LDL and the risk of coronary events, as well as a similar link between CRP levels...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics